Skip to content
value.today

Escient Pharmaceuticals Inc

🇺🇸 San Diego, California, USABiotechnologyFounded 2017
Total raised
$109 M
3 rounds on record
Latest round
$60 M
Nov 2022
First round on record
Mar 2018
Today
Private
No later event on record

Funding rounds

3 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of Escient Pharmaceuticals Inc
MonthRaisedRaiseSizeInvestorsSoldFiling
Nov 2022$60 MNo. 3$50 to $250 million

Escient Pharmaceuticals Inc: Raise no. 3, Nov 2022

Investors in this round

22 investors had bought by the notice of Nov 28, 2022: 22 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$60 M of $120 M offered; $60 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Aaron Sereda Mishel · Executive Officer
  • Joshua Grass · Executive Officer, Director
  • Marcus Boehm · Executive Officer
  • Andrew Sereda Schwab · Director
  • Charles Sereda Zuker · Director
  • Jason Sereda Hafler · Director
  • JeenJoo Sereda Kang · Director
  • Kathleen Sereda Glaub · Director
  • Kevin Sereda Raidy · Director
  • Peter Sereda Hirth · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the amounts: “"The total offering amount is fully committed by investors participating in the initial closing (the ""Investors""). The above noted remainder of the offering will be sold to the Investors upon satisfaction or waiver of certain milestone conditions."”

Signed by Joshua Grass, Chief Executive Officer. Source: SEC Form D, newest notice filed Nov 28, 2022. Read the notice at the SEC.

equitySEC
Aug 2020$39 MNo. 2$10 to $50 million

Escient Pharmaceuticals Inc: Raise no. 2, Aug 2020

Investors in this round

18 investors had bought by the notice of Sep 18, 2020: 18 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$39 M of $78 M offered; $39 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Alain Baron · Executive Officer, Director
  • Marcus Boehm · Executive Officer
  • Andrew Schwab · Director
  • Charles Zuker · Director
  • Jason Hafler · Director
  • JeenJoo Kang · Director
  • Kathleen Glaub · Director
  • Kevin Raidy · Director
  • Peter Hirth · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Alain Baron, Chief Executive Officer. Source: SEC Form D and 1 amendment, newest notice filed Sep 18, 2020. Read the notice at the SEC.

equitySEC
Mar 2018$10 MNo. 1$10 to $50 million

Escient Pharmaceuticals Inc: Raise no. 1, Mar 2018

Investors in this round

10 investors had bought by the notice of Apr 9, 2018: 10 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$10 M of $40 M offered; $30 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Alain Baron · Executive Officer, Director
  • Marcus Boehm · Executive Officer
  • Andrew Schwab · Director
  • JeenJoo Kang · Director
  • Robert Tjian · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Alain Baron, Chief Executive Officer. Source: SEC Form D, newest notice filed Apr 9, 2018. Read the notice at the SEC.

equitySEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Escient Pharmaceuticals Inc chose not to state its revenue in its newest notice of a funding round (Nov 2022).

    SEC Form D · Nov 2022

  • The industry group it chose in its notices: Biotechnology.

    SEC Form D · Nov 2022

That is all the official record says: Escient Pharmaceuticals Inc has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.

Products and services#

No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).

Investors#

No investor of Escient Pharmaceuticals Inc is named in an official source we use. Its funding notices give only how many investors bought, not who they are.

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 3 rounds above had up to 22 investors.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Escient Pharmaceuticals Inc
NameRoleNamed in
Aaron Sereda MishelExecutive officerNov 2022
Joshua GrassExecutive officerNov 2022
Marcus BoehmExecutive officerNov 2022
Alain BaronExecutive officerSep 2020
Andrew Sereda SchwabDirectorNov 2022
Charles Sereda ZukerDirectorNov 2022
Jason Sereda HaflerDirectorNov 2022
JeenJoo Sereda KangDirectorNov 2022
Joshua GrassDirectorNov 2022
Kathleen Sereda GlaubDirectorNov 2022
Kevin Sereda RaidyDirectorNov 2022
Peter Sereda HirthDirectorNov 2022
Alain BaronDirectorSep 2020
Andrew SchwabDirectorSep 2020
Charles ZukerDirectorSep 2020
Jason HaflerDirectorSep 2020
JeenJoo KangDirectorSep 2020
Kathleen GlaubDirectorSep 2020
Kevin RaidyDirectorSep 2020
Peter HirthDirectorSep 2020
Robert TjianDirectorApr 2018